From 05/11/2015 Pyc asx announcement re injecting tumors. My thought was a compete turn around from what i thought initially. Surely this has value if it works to reduce tumour even if only to allow time for other therapies to take hold. It seems tragic that these things are driven by cost and profit rather than human need, although that is obviously how the corporate medical model works sadly.
Perth, Australia 5 November 2015: A leading cancer expert based at the Harry Perkins Institute in Perth has conducted an expanded study in a mouse model of breast cancer that has: • confirmed Phylogica’s peptide-OmoMyc fusion significantly reduces tumour size following direct injection of the drug into the tumour • demonstrated that inhibition of tumour growth was sustained even after cessation of treatment – suggesting prolonged impact of drug • No evidence for Phylomer-associated toxicity was observed • confirmed Phylogica at forefront of efforts to develop first-in-class biologics inhibitors of Myc – a highly sought after cancer target
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)